此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

伊沙匹隆和替西罗莫司治疗转移性或无法通过手术切除的实体瘤患者

2026年11月10日 更新者:National Cancer Institute (NCI)

Ixabepilone 和替西罗莫司在成年晚期实体瘤患者中的 I 期研究

This phase I trial studies the side effects and best dose of ixabepilone and temsirolimus in treating patients with solid tumors that have spread from the primary site to other places in the body or cannot be removed by surgery. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving ixabepilone together with temsirolimus may kill more tumor cells.

研究概览

详细说明

PRIMARY OBJECTIVES:

I. To determine the maximally tolerated dose (MTD) of the combination of ixabepilone and temsirolimus in patients with advanced solid tumors.

II. To describe toxicity profiles associated with the combination of ixabepilone and temsirolimus.

III. To assess preliminary efficacy of the combination of ixabepilone and temsirolimus.

OUTLINE: This is a dose-escalation study.

Patients receive ixabepilone intravenously (IV) over 3 hours on day 1 and temsirolimus IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 3 months.

研究类型

介入性

注册 (实际的)

22

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Florida
      • Jacksonville、Florida、美国、32224-9980
        • Mayo Clinic in Florida
    • Minnesota
      • Rochester、Minnesota、美国、55905
        • Mayo Clinic in Rochester

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adult patients with histologically confirmed solid tumor malignancy that is metastatic or unresectable and for which standard curative measures or other therapy that provide survival benefit do not exist or are no longer effective
  • Patients may not have had more than two systemic therapeutic regimens in the metastatic disease setting with the following exceptions: hormonal therapy (e.g. tamoxifen, aromatase inhibitors, anti-androgen therapy, etc.)
  • Patients with non-measurable, but assessable, disease will be allowed
  • Absolute neutrophil count >= 1500/mcL
  • Hemoglobin >= 9.0 g/dL
  • Platelets >= 100,000/mcL
  • Total bilirubin < 1.5 mg/dL
  • Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) or serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) =< 2.5 x institutional upper limit of normal (ULN) in the absence of hepatic metastasis; SGPT (ALT) =< 3 x ULN or SGOT (AST) =< 5 x ULN in the presence of hepatic metastasis
  • Creatinine =< 1.5 x ULN
  • International normalized ratio (INR) =< 1.4 for patients not on warfarin (Coumadin)
  • INR range of 2.0-3.0 for patients on therapeutic doses of warfarin (Coumadin)
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1, or 2
  • Ability to provide informed consent
  • Willingness to return to a Mayo Clinic institution for follow up
  • Life expectancy >= 84 days (12 weeks)
  • Women of childbearing potential only: negative serum pregnancy test done =< 7 days prior to registration

Exclusion Criteria:

  • Known standard therapy for the patient's disease that is potentially curative or definitely capable of extending life expectancy

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, uncontrolled diabetes or with hemoglobin A1c (HbA1C) > 8, or psychiatric illness/social situations that would limit compliance with study requirements

  • Any of the following prior therapies:

    • Chemotherapy =< 28 days prior to registration
    • Mitomycin C/nitrosoureas =< 42 days prior to registration
    • Immunotherapy =< 28 days prior to registration
    • Biologic therapy =< 28 days prior to registration
    • Radiation therapy =< 28 days prior to registration
    • Radiation to > 25% of bone marrow
  • Failure to fully recover from acute, reversible effects of prior chemotherapy regardless of interval since last treatment

  • New York Heart Association classification III or IV

  • Known central nervous system (CNS) metastases or seizure disorder; patients with known brain metastases that have been successfully treated and stable for > 6 months without requirement for corticosteroids and without seizure activity will be eligible

  • Any of the following:

    • Pregnant women
    • Nursing women
    • Men or women of childbearing potential who are unwilling to employ adequate contraception
  • Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation)

  • Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens

  • Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive

  • Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm

  • History of myocardial infarction =< 168 days (6 months), or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias

  • >= Grade 2 sensory neuropathy

  • >= Grade 2 hypertriglyceridemia

  • >= Grade 2 hypercholesterolemia

  • Patients on medication considered strong cytochrome P450 3A4 (CYP3A4) inducers (efavirenz, nevirapine, carbamazepine, phenobarbital, phenytoin, pioglitazone, rifabutin, rifampin, St. John's wort) or CYP3A4 inhibitors (indinavir, nelfinavir, ritonavir, clarithromycin, itraconazole, ketoconazole, nefazodone, saquinavir, telithromycin) unless the medication can be substituted with another agent

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Treatment (ixabepilone, temsirolimus)

Patients receive ixabepilone IV over 3 hours on day 1 and temsirolimus IV over 30-60 minutes on days 1 and 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Correlative studies

Given IV

其他名称:
  • 托利塞尔
  • CCI-779
  • CCI-779雷帕霉素类似物
  • 细胞周期抑制剂 779
  • 雷帕霉素类似物
  • 雷帕霉素类似物 CCI-779
  • CCI 779
  • CCI779

Given IV

其他名称:
  • BMS-247550
  • 伊仙普拉
  • (1S,3S,7S,10R,11S,12S,16R)-7,11-二羟基-8,8,10,12,16-五甲基-3-[(1E)-1-甲基-2-(2-甲基-4-噻唑基)乙烯基]-17-oxa-4-氮杂双环[14.1.0]heptadecane-5,9-dione
  • 氮杂坡霉素B
  • 建筑管理系统 247550
  • BMS247550
  • 埃博霉素
  • 埃坡霉素 B BMS 247550

研究衡量的是什么?

主要结果指标

结果测量
大体时间
伊沙匹隆和替西罗莫司联合用药的 MTD,定义为在至少三分之一的患者(最多 6 名新患者中的至少 2 名)中诱发剂量限制性毒性的最低剂量以下的剂量水平
大体时间:21天
21天

次要结果测量

结果测量
措施说明
大体时间
治疗失败时间
大体时间:从注册到记录进展、不可接受的毒性或患者拒绝继续参与,评估长达 3 个月
从注册到记录进展、不可接受的毒性或患者拒绝继续参与,评估长达 3 个月
出现任何治疗相关毒性的时间
大体时间:长达 3 个月
长达 3 个月
治疗相关 3+ 级毒性的时间
大体时间:长达 3 个月
长达 3 个月
血液学最低点之前的时间(白细胞、中性粒细胞绝对计数、血小板)
大体时间:长达 3 个月
长达 3 个月
进展时间
大体时间:长达 3 个月
长达 3 个月
Incidence of adverse events graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
大体时间:Up to 3 months

The number and severity of all adverse events (overall, by dose-level, and by tumor group) will be tabulated and summarized in this patient population.

Up to 3 months
Incidence of overall toxicity graded according to Common Toxicity Criteria standard grading
大体时间:Up to 3 months

Frequency distributions, graphical techniques and other descriptive measures will form the basis of these analyses.

Up to 3 months
Best response, defined to be the best objective status recorded from the start of the treatment until disease progression/recurrence
大体时间:Up to 3 months

Responses will be summarized by simple descriptive summary statistics delineating complete and partial responses as well as stable and progressive disease in this patient population (overall and by tumor group).

Up to 3 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Keith C Bible、Mayo Clinic

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2011年6月27日

初级完成 (实际的)

2018年6月26日

研究完成 (估计的)

2027年3月19日

研究注册日期

首次提交

2011年6月16日

首先提交符合 QC 标准的

2011年6月16日

首次发布 (估计的)

2011年6月17日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月10日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • NCI-2012-02907
  • P30CA015083 (美国 NIH 拨款/合同)
  • U01CA069912 (美国 NIH 拨款/合同)
  • UM1CA186686 (美国 NIH 拨款/合同)
  • NCI-2012-02907 (注册表标识符:CTRP (Clinical Trial Reporting Program))
  • NCI-2012-01136
  • CDR0000702380
  • NCI-2011-01140
  • MC1013 (其他标识符:Mayo Clinic in Rochester)
  • 8814 (其他标识符:CTEP)

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅